GW Henssler & Associates Ltd. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 167,056 shares of the biopharmaceutical company’s stock after purchasing an additional 6,547 shares during the period. Gilead Sciences comprises 1.4% of GW Henssler & Associates Ltd.’s holdings, making the stock its 24th largest position. GW Henssler & Associates Ltd.’s holdings in Gilead Sciences were worth $13,535,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of the stock. Migdal Insurance & Financial Holdings Ltd. bought a new position in Gilead Sciences in the 2nd quarter valued at about $147,000. Hanson & Doremus Investment Management increased its holdings in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares during the period. Rowland & Co. Investment Counsel ADV bought a new position in shares of Gilead Sciences during the second quarter worth approximately $153,000. Finally, Capstone Investment Advisors Netherlands B.V. bought a new position in shares of Gilead Sciences during the second quarter worth approximately $172,000. Institutional investors and hedge funds own 75.95% of the company’s stock.
GILD has been the topic of a number of research analyst reports. Credit Suisse Group set a $80.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a research report on Wednesday, January 3rd. Oppenheimer began coverage on shares of Gilead Sciences in a report on Thursday, October 5th. They issued a “market perform” rating on the stock. Mizuho boosted their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Leerink Swann boosted their target price on shares of Gilead Sciences from $87.00 to $89.00 and gave the company a “market perform” rating in a report on Thursday, October 5th. Finally, BMO Capital Markets decreased their price target on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $85.53.
Shares of Gilead Sciences, Inc. (GILD) opened at $81.74 on Thursday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The firm has a market cap of $106,750.00, a P/E ratio of 9.30, a P/E/G ratio of -1.71 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.75 EPS. analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s payout ratio is 23.66%.
In related news, EVP Gregg H. Alton sold 30,000 shares of the stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $79.00, for a total transaction of $2,370,000.00. Following the transaction, the executive vice president now owns 57,114 shares of the company’s stock, valued at approximately $4,512,006. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. Insiders sold a total of 491,666 shares of company stock worth $36,442,567 in the last three months. Insiders own 1.30% of the company’s stock.
WARNING: “Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by GW Henssler & Associates Ltd.” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/18/gw-henssler-associates-ltd-buys-6547-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.